{"id":15381,"date":"2025-09-03T08:07:44","date_gmt":"2025-09-03T06:07:44","guid":{"rendered":"https:\/\/saludporderecho.org\/?p=15381"},"modified":"2025-09-12T14:33:48","modified_gmt":"2025-09-12T12:33:48","slug":"lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most","status":"publish","type":"post","link":"https:\/\/saludporderecho.org\/en\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\/","title":{"rendered":"Lenacapavir: the new HIV injection that Gilead is delaying in the countries that need it most"},"content":{"rendered":"<p data-start=\"116\" data-end=\"533\">On June 18, the U.S. Food and Drug Administration approved long-acting injectable lenacapavir for HIV prevention. A month later, the European Medicines Agency recommended its authorization, which was officially formalized by the European Commission last week. In Europe, the drug will be marketed under the name <strong data-start=\"428\" data-end=\"438\">Yeytuo<\/strong>, and its availability will now depend on price and reimbursement negotiations in each country.<\/p>\n<p data-start=\"535\" data-end=\"1068\">This is a historic breakthrough, as lenacapavir is the first pre-exposure prophylaxis (PrEP) option that can be administered only twice a year\u2014a tool that could mark a turning point in the fight against HIV. Clinical trials have shown that it provides near-complete protection against infection. This advance is especially important for cisgender women in sub-Saharan Africa, sex workers, LGTBIQ+ people, and people who use drugs\u2014groups for whom existing tools such as daily oral PrEP or condoms have not been sufficiently effective.<\/p>\n<p data-start=\"1070\" data-end=\"1520\">However, this potential risks being restricted to very few people, even in high-income countries where the price will pose a major barrier to access. Last year, we already warned that the voluntary license promoted by the company was not enough. Added to this is the fact that Gilead will remain the sole global supplier of the drug until 2027, meaning that its decisions on pricing, registration, and transparency will directly impact global access.<\/p>\n<p data-start=\"1070\" data-end=\"1520\"><iframe id=\"datawrapper-chart-YToBc\" style=\"width: 0; min-width: 100% !important; border: none;\" title=\"Licencia Voluntaria de Gilead para Lenacapavir: una soluci\u00f3n insuficiente\" src=\"https:\/\/datawrapper.dwcdn.net\/YToBc\/2\/\" height=\"449\" frameborder=\"0\" scrolling=\"no\" aria-label=\"Choropleth map\" data-external=\"1\"><\/iframe><script type=\"text\/javascript\">!function(){\"use strict\";window.addEventListener(\"message\",function(a){if(void 0!==a.data[\"datawrapper-height\"]){var e=document.querySelectorAll(\"iframe\");for(var t in a.data[\"datawrapper-height\"])for(var r,i=0;r=e[i];i++)if(r.contentWindow===a.source){var d=a.data[\"datawrapper-height\"][t]+\"px\";r.style.height=d}}})}();<\/p>\n<p><\/script><\/p>\n<p data-start=\"1522\" data-end=\"1552\"><strong data-start=\"1522\" data-end=\"1552\">Registration: a bottleneck<\/strong><\/p>\n<p data-start=\"1554\" data-end=\"1898\">Regulatory approval in each country is a prerequisite for HIV programs to roll out lenacapavir on a large scale. But Gilead has prioritized submissions in the most profitable markets (such as the United States, the European Union, the United Kingdom, Australia, and Canada), where the drug may be priced at over <strong data-start=\"1866\" data-end=\"1897\">$28,000 per person per year<\/strong>.<\/p>\n<p data-start=\"1900\" data-end=\"2071\">This is despite independent studies showing that lenacapavir could be manufactured for as little as <strong data-start=\"2000\" data-end=\"2016\">$25 per year<\/strong> if generics and large-scale production were available.<\/p>\n<p data-start=\"2073\" data-end=\"2469\">Meanwhile, the situation in low- and middle-income countries remains unclear and troubling. Of the countries that participated in the PURPOSE clinical trials, only South Africa and Brazil have received registration submissions, both still pending approval. Although Gilead announced a group of \u201cpriority countries\u201d in Africa and Asia, so far only South Africa has a formal application in process.<\/p>\n<p data-start=\"2471\" data-end=\"2633\">At the same time, the EU\u2019s accelerated approval pathway (EU-Medicines for All) covers just eight countries, leaving out most of those hardest hit by the epidemic.<\/p>\n<p data-start=\"2635\" data-end=\"2670\"><strong data-start=\"2635\" data-end=\"2670\">Lack of transparency and delays<\/strong><\/p>\n<p data-start=\"2672\" data-end=\"3155\">Together with other civil society organizations worldwide, Salud por Derecho has denounced Gilead\u2019s lack of transparency around its regulatory and pricing plans. Despite having the option, the company has not yet applied for World Health Organization (WHO) prequalification\u2014a critical step to speed up availability in low- and middle-income countries. Nor has it committed to the WHO Collaborative Registration Procedure, which would allow national approvals in as little as 90 days.<\/p>\n<p data-start=\"3157\" data-end=\"3517\">The absence of these mechanisms means that most countries will face lengthy, fragmented processes, with direct consequences for health, since every delay translates into infections that could have been prevented. In May, global estimates of new HIV infections rose from 3,500 to 5,800 per day, underscoring the urgency of making new prevention tools available.<\/p>\n<p data-start=\"3519\" data-end=\"3539\"><strong data-start=\"3519\" data-end=\"3539\"><img decoding=\"async\" class=\"aligncenter size-full wp-image-15408\" src=\"https:\/\/saludporderecho.org\/wp-content\/uploads\/2025\/09\/image.png\" alt=\"\" width=\"964\" height=\"535\" srcset=\"https:\/\/saludporderecho.org\/wp-content\/uploads\/2025\/09\/image.png 964w, https:\/\/saludporderecho.org\/wp-content\/uploads\/2025\/09\/image-300x166.png 300w, https:\/\/saludporderecho.org\/wp-content\/uploads\/2025\/09\/image-768x426.png 768w\" sizes=\"(max-width: 964px) 100vw, 964px\" \/><\/strong><\/p>\n<p data-start=\"3519\" data-end=\"3539\"><strong data-start=\"3519\" data-end=\"3539\">Letter to Gilead<\/strong><\/p>\n<p data-start=\"3541\" data-end=\"3863\">Last August, Salud por Derecho, together with an international coalition of 278 organizations and individual signatories\u2014including Health GAP, Public Citizen, Doctors Without Borders, ABIA Brazil, Health Justice Initiative, and Treatment Action Campaign\u2014sent a letter to Gilead CEO Daniel O\u2019Day demanding that the company:<\/p>\n<ul>\n<li data-start=\"3867\" data-end=\"3943\">Accelerate regulatory submissions in all low- and middle-income countries.<\/li>\n<li data-start=\"3867\" data-end=\"3943\">Publish the list of countries included in the EU-Medicines for All pathway.<\/li>\n<li data-start=\"3867\" data-end=\"3943\">Urgently apply for WHO prequalification and make use of the collaborative registration procedure.<\/li>\n<li data-start=\"3867\" data-end=\"3943\">Ensure affordable and transparent pricing.<\/li>\n<\/ul>\n<p data-start=\"4174\" data-end=\"4543\">Lenacapavir has the potential to transform HIV prevention. But for that promise to be fulfilled, Gilead must take responsibility by speeding up registration processes, offering fair prices, and acting with full transparency. Otherwise, we risk seeing a revolutionary tool reserved for a privileged few, when what is needed is a global, urgent, and equitable response.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On June 18, the U.S. Food and Drug Administration approved long-acting injectable lenacapavir for HIV prevention. A month later, the European Medicines Agency recommended its authorization, which was officially formalized<\/p>\n","protected":false},"author":2,"featured_media":15378,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[309],"tags":[1210,696,1209,428],"class_list":["post-15381","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-slider-en","tag-lenacapavir-en","tag-sin-categoria","tag-sin-categoria-en-17","tag-vih-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lenacapavir: the new HIV injection that Gilead is delaying in the countries that need it most | Salud por Derecho<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/saludporderecho.org\/en\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Lenacapavir: the new HIV injection that Gilead is delaying in the countries that need it most | Salud por Derecho\" \/>\n<meta name=\"twitter:description\" content=\"On June 18, the U.S. Food and Drug Administration approved long-acting injectable lenacapavir for HIV prevention. A month later, the European Medicines Agency recommended its authorization, which was officially formalized\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/saludporderecho.org\/wp-content\/uploads\/2025\/09\/Gilead_protest2.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@Saludporderecho\" \/>\n<meta name=\"twitter:site\" content=\"@Saludporderecho\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Salud\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/en\\\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/en\\\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\\\/\"},\"author\":{\"name\":\"Salud\",\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/#\\\/schema\\\/person\\\/d51b5f00da11ad5c8809925c829fbcea\"},\"headline\":\"Lenacapavir: the new HIV injection that Gilead is delaying in the countries that need it most\",\"datePublished\":\"2025-09-03T06:07:44+00:00\",\"dateModified\":\"2025-09-12T12:33:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/en\\\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\\\/\"},\"wordCount\":669,\"publisher\":{\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/en\\\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/saludporderecho.org\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/Gilead_protest2.jpg\",\"keywords\":[\"lenacapavir\",\"Sin categor\u00eda\",\"Sin categor\u00eda\",\"VIH\"],\"articleSection\":[\"Home Slider\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/en\\\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\\\/\",\"url\":\"https:\\\/\\\/saludporderecho.org\\\/en\\\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\\\/\",\"name\":\"Lenacapavir: the new HIV injection that Gilead is delaying in the countries that need it most | Salud por Derecho\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/en\\\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/en\\\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/saludporderecho.org\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/Gilead_protest2.jpg\",\"datePublished\":\"2025-09-03T06:07:44+00:00\",\"dateModified\":\"2025-09-12T12:33:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/en\\\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/saludporderecho.org\\\/en\\\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/en\\\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\\\/#primaryimage\",\"url\":\"https:\\\/\\\/saludporderecho.org\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/Gilead_protest2.jpg\",\"contentUrl\":\"https:\\\/\\\/saludporderecho.org\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/Gilead_protest2.jpg\",\"width\":900,\"height\":587},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/en\\\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/saludporderecho.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lenacapavir: the new HIV injection that Gilead is delaying in the countries that need it most\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/#website\",\"url\":\"https:\\\/\\\/saludporderecho.org\\\/\",\"name\":\"Salud por Derecho\",\"description\":\"Salud por Derecho\",\"publisher\":{\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/saludporderecho.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/#organization\",\"name\":\"Salud por Derecho\",\"url\":\"https:\\\/\\\/saludporderecho.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/saludporderecho.org\\\/wp-content\\\/uploads\\\/2018\\\/02\\\/1490208884021_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/saludporderecho.org\\\/wp-content\\\/uploads\\\/2018\\\/02\\\/1490208884021_logo.jpg\",\"width\":107,\"height\":95,\"caption\":\"Salud por Derecho\"},\"image\":{\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/saludporderecho\",\"https:\\\/\\\/x.com\\\/Saludporderecho\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/saludxderecho\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/saludporderecho.org\\\/#\\\/schema\\\/person\\\/d51b5f00da11ad5c8809925c829fbcea\",\"name\":\"Salud\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de799b69a115cd4d753831af1129f8209a73858c9fdde3ee5ae305df4eb52b65?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de799b69a115cd4d753831af1129f8209a73858c9fdde3ee5ae305df4eb52b65?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de799b69a115cd4d753831af1129f8209a73858c9fdde3ee5ae305df4eb52b65?s=96&d=mm&r=g\",\"caption\":\"Salud\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lenacapavir: the new HIV injection that Gilead is delaying in the countries that need it most | Salud por Derecho","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/saludporderecho.org\/en\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\/","twitter_card":"summary_large_image","twitter_title":"Lenacapavir: the new HIV injection that Gilead is delaying in the countries that need it most | Salud por Derecho","twitter_description":"On June 18, the U.S. Food and Drug Administration approved long-acting injectable lenacapavir for HIV prevention. A month later, the European Medicines Agency recommended its authorization, which was officially formalized","twitter_image":"https:\/\/saludporderecho.org\/wp-content\/uploads\/2025\/09\/Gilead_protest2.jpg","twitter_creator":"@Saludporderecho","twitter_site":"@Saludporderecho","twitter_misc":{"Written by":"Salud","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/saludporderecho.org\/en\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\/#article","isPartOf":{"@id":"https:\/\/saludporderecho.org\/en\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\/"},"author":{"name":"Salud","@id":"https:\/\/saludporderecho.org\/#\/schema\/person\/d51b5f00da11ad5c8809925c829fbcea"},"headline":"Lenacapavir: the new HIV injection that Gilead is delaying in the countries that need it most","datePublished":"2025-09-03T06:07:44+00:00","dateModified":"2025-09-12T12:33:48+00:00","mainEntityOfPage":{"@id":"https:\/\/saludporderecho.org\/en\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\/"},"wordCount":669,"publisher":{"@id":"https:\/\/saludporderecho.org\/#organization"},"image":{"@id":"https:\/\/saludporderecho.org\/en\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\/#primaryimage"},"thumbnailUrl":"https:\/\/saludporderecho.org\/wp-content\/uploads\/2025\/09\/Gilead_protest2.jpg","keywords":["lenacapavir","Sin categor\u00eda","Sin categor\u00eda","VIH"],"articleSection":["Home Slider"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/saludporderecho.org\/en\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\/","url":"https:\/\/saludporderecho.org\/en\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\/","name":"Lenacapavir: the new HIV injection that Gilead is delaying in the countries that need it most | Salud por Derecho","isPartOf":{"@id":"https:\/\/saludporderecho.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/saludporderecho.org\/en\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\/#primaryimage"},"image":{"@id":"https:\/\/saludporderecho.org\/en\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\/#primaryimage"},"thumbnailUrl":"https:\/\/saludporderecho.org\/wp-content\/uploads\/2025\/09\/Gilead_protest2.jpg","datePublished":"2025-09-03T06:07:44+00:00","dateModified":"2025-09-12T12:33:48+00:00","breadcrumb":{"@id":"https:\/\/saludporderecho.org\/en\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/saludporderecho.org\/en\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/saludporderecho.org\/en\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\/#primaryimage","url":"https:\/\/saludporderecho.org\/wp-content\/uploads\/2025\/09\/Gilead_protest2.jpg","contentUrl":"https:\/\/saludporderecho.org\/wp-content\/uploads\/2025\/09\/Gilead_protest2.jpg","width":900,"height":587},{"@type":"BreadcrumbList","@id":"https:\/\/saludporderecho.org\/en\/lenacapavir-the-new-hiv-injection-that-gilead-is-delaying-in-the-countries-that-need-it-most\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/saludporderecho.org\/en\/"},{"@type":"ListItem","position":2,"name":"Lenacapavir: the new HIV injection that Gilead is delaying in the countries that need it most"}]},{"@type":"WebSite","@id":"https:\/\/saludporderecho.org\/#website","url":"https:\/\/saludporderecho.org\/","name":"Salud por Derecho","description":"Salud por Derecho","publisher":{"@id":"https:\/\/saludporderecho.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/saludporderecho.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/saludporderecho.org\/#organization","name":"Salud por Derecho","url":"https:\/\/saludporderecho.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/saludporderecho.org\/#\/schema\/logo\/image\/","url":"https:\/\/saludporderecho.org\/wp-content\/uploads\/2018\/02\/1490208884021_logo.jpg","contentUrl":"https:\/\/saludporderecho.org\/wp-content\/uploads\/2018\/02\/1490208884021_logo.jpg","width":107,"height":95,"caption":"Salud por Derecho"},"image":{"@id":"https:\/\/saludporderecho.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/saludporderecho","https:\/\/x.com\/Saludporderecho","https:\/\/www.youtube.com\/user\/saludxderecho"]},{"@type":"Person","@id":"https:\/\/saludporderecho.org\/#\/schema\/person\/d51b5f00da11ad5c8809925c829fbcea","name":"Salud","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/de799b69a115cd4d753831af1129f8209a73858c9fdde3ee5ae305df4eb52b65?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/de799b69a115cd4d753831af1129f8209a73858c9fdde3ee5ae305df4eb52b65?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/de799b69a115cd4d753831af1129f8209a73858c9fdde3ee5ae305df4eb52b65?s=96&d=mm&r=g","caption":"Salud"}}]}},"_links":{"self":[{"href":"https:\/\/saludporderecho.org\/en\/wp-json\/wp\/v2\/posts\/15381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/saludporderecho.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/saludporderecho.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/saludporderecho.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/saludporderecho.org\/en\/wp-json\/wp\/v2\/comments?post=15381"}],"version-history":[{"count":7,"href":"https:\/\/saludporderecho.org\/en\/wp-json\/wp\/v2\/posts\/15381\/revisions"}],"predecessor-version":[{"id":15411,"href":"https:\/\/saludporderecho.org\/en\/wp-json\/wp\/v2\/posts\/15381\/revisions\/15411"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/saludporderecho.org\/en\/wp-json\/wp\/v2\/media\/15378"}],"wp:attachment":[{"href":"https:\/\/saludporderecho.org\/en\/wp-json\/wp\/v2\/media?parent=15381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/saludporderecho.org\/en\/wp-json\/wp\/v2\/categories?post=15381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/saludporderecho.org\/en\/wp-json\/wp\/v2\/tags?post=15381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}